SEC Form 4 · accession 0001179110-18-006160
MOMENTA PHARMACEUTICALS INC · MNTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Craig A Wheeler
Officer — President & CEO · Director
Period of report
May 1, 2018
Accepted (ET)
May 3, 2018 · 4:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235010
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 1, 2018 | M | 32,433 | $10.43 | A | 230,012 | D | |
| Common StockF2 | May 1, 2018 | S | 32,433 | $20.68 | D | 197,579 | D | |
| Common StockF3 | May 1, 2018 | S | 5,004 | $20.75 | D | 349,645 | I | Craig Wheeler Revocable Trust |
| Common Stock | May 2, 2018 | M | 33,333 | $10.43 | A | 230,912 | D | |
| Common Stock | May 2, 2018 | S | 33,333 | $21.00 | D | 197,579 | D | |
| Common Stock | May 2, 2018 | S | 10,000 | $21.00 | D | 339,645 | I | Craig Wheeler Revocable Trust |
| Common Stock | holding | — | — | — | 45,980 | I | Craig A Wheeler 2016 Annuity Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $10.43 | May 1, 2018 | M | 32,433 | D | Feb 25, 2013 | Feb 25, 2019 | Common Stock | 32,433 | 33,333 | D |
| Stock Option (Right to Buy) | $10.43 | May 2, 2018 | M | 33,333 | D | Feb 25, 2013 | Feb 25, 2019 | Common Stock | 33,333 | 0 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016.
- F2This transaction was executed in multiple trades at prices ranging from $20.45 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F3This transaction was executed in multiple trades at prices ranging from $20.65 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.